Discovery and development of gliflozins information
Gliflozins are a class of drugs in the treatment of type 2 diabetes (T2D). They act by inhibiting sodium/glucose cotransporter 2 (SGLT-2), and are therefore also called SGLT-2 inhibitors. The efficacy of the drug is dependent on renal excretion and prevents glucose from going into blood circulation by promoting glucosuria. The mechanism of action is insulin independent.
Three drugs have been accepted by the Food and Drug Administration (FDA) in the United States; dapagliflozin, canagliflozin and empagliflozin. Canagliflozin was the first SGLT-2 inhibitor that was approved by the FDA, being accepted in March 2013. Dapagliflozin and empagliflozin were accepted in 2014.
and 15 Related for: Discovery and development of gliflozins information
Gliflozins are a class of drugs in the treatment of type 2 diabetes (T2D). They act by inhibiting sodium/glucose cotransporter 2 (SGLT-2), and are therefore...
called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney)...
examining hormones secreted during eating, and testing them on pig pancreases, leading to the discoveryof GLP-1's significant potency in 1988. Their...
"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept". Molecular...
Pharmacogenetics of new classes of antidiabetic drugs. Bosn J of Basic Med Sci. 2021. DOI: https://doi.org/10.17305/bjbms.2021.5646 "SGLT2 Inhibitors (Gliflozins) –...
tofogliflozin applies to the anhydrous compound and the drug form is referred to as tofogliflozin hydrate. Gliflozin "International Nonproprietary Names for Pharmaceutical...
serum creatinine was noted with 16 weeks use of saroglitazar at 4mg/day dose. In December 2016, Zydus Discovery DMCC, a research subsidiary Zydus Lifesciences...
diabetes". Drugs in the gliflozin class (SGLT2 inhibitors), which are generally used for type 2 diabetes, have been associated with cases of diabetic ketoacidosis...
Berthel S (2010). "Diabetes Drugs: Present and Emerging". Burger's Medicinal Chemistry and Drug Discovery. pp. 1–38. doi:10.1002/0471266949.bmc198. ISBN 978-0471266945...
Kawamatsu Y, Fujita T, Meguro K, Ikeda H (November 2002). "[Discoveryanddevelopmentof a new insulin sensitizing agent, pioglitazone]". Yakugaku Zasshi...
oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in...
Retrieved 3 March 2019. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 450. ISBN 9783527607495. Archived from the original...
Analogue-based Drug Discovery. John Wiley & Sons. p. 450. ISBN 9783527607495. Chen X, Yang L, Zhai SD (December 2012). "Risk of cardiovascular disease and all-cause...
ChemLDplus advanced database Ravina E, Kubinyi H (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. Wiley. p. 215. Miller...
Global Information